Riyadh-Mubasher: Albilad Capital placed a ‘Neutral’ recommendation on Dallah Healthcare, setting the fair value at SAR 135.

The research firm said Dallah’s second-quarter financials were negatively impacted by low number of outpatients during the month of Ramadan, which weighed on revenues.  

Dallah posted net earnings of SAR 35.9 million for the second quarter of 2015, rising 5% compared with SAR 34.3 million in the year-ago period.

Net earnings for the first half of 2015 rose 12% year-on-year from SAR 74.8 million to SAR 83.7 million.